Amanta Healthcare IPO Review
About the Company
Founded in 1994, Amanta Healthcare Limited is a pharma company specializing in sterile intravenous (IV) fluids, injectables, and related healthcare products. It caters to hospitals, nursing homes, and clinics across India and also exports to international markets. Its product range covers large-volume parenterals (LVPs), small-volume parenterals (SVPs), and specialized sterile solutions. The company has WHO-GMP compliant facilities.
IPO Details
-
Price Band: Rs. 120–126 per share
-
Lot Size: 119 shares
-
Minimum Investment: Rs. 14,994 (at upper band)
-
Listing: BSE SME / NSE SME (to be confirmed)
Financial Performance (Rs. crore)
| Particulars | FY23 | FY24 | FY25 |
|---|---|---|---|
| Total Income | 262.70 | 281.61 | 276.09 |
| EBITDA | 56.31 | 58.76 | 61.05 |
| Profit After Tax | -2.11 | 3.63 | 10.50 |
| Net Worth | 62.88 | 66.29 | 96.39 |
| Borrowings | 215.66 | 205.23 | 195.00 |
Analysis:
-
Revenue has been stable around Rs. 260–280 crore over the last three years.
-
Profitability improved sharply in FY25, with PAT rising to Rs. 10.5 crore (vs. Rs. 3.63 crore in FY24 and a loss in FY23).
-
EBITDA margins are healthy, consistently above 20%.
-
Net worth strengthened, while borrowings declined gradually – indicating balance sheet improvement.
Valuation & Verdict
At the upper band of Rs. 126, Amanta Healthcare commands a P/E multiple of ~35x FY25 earnings. While valuations appear slightly on the higher side compared to some listed SME peers, the stable revenue base, rising margins, and sectoral demand visibility in healthcare justify a premium.
👉 Chanakya Verdict: Investors with long-term outlook may subscribe. Short-term listing gains may depend on market sentiment.
Quicklinks
